Real-Time Trial Monitoring
Centralized KPI monitoring, predictive alerts, and RBQM dashboards
Real-Time Trial Monitoring
Centralized KPI dashboard, risk signals, and site performance across your portfolio.
Enrollment👥
52%
187/360
18.5/mo
Screen Fail Rate🚫
34.2%
Protocol Deviations📋
4.8%
Query Rate\u2753
2.1per 1K
Data Entry Lag\u23F1\uFE0F
3.2days
SAE Count\u26A0\uFE0F
12
Composite Risk Score
42 / 100
Medium Risk⚡ warning2
ℹ️ info2
Risk Alerts
4 active⚡ warning
Enrollment rate 18.5/month vs. planned 22/month — at current pace, enrollment completion delayed by ~8 weeks (projected Sep 2027 vs. target Jul 2027)
enrollment⚡ warning
2 cases of Grade 3 hyperphosphatemia reported (FGFR class effect) — DSMB review scheduled for Apr 2026. No dose-limiting toxicities.
safetyℹ️ info
Screen failure rate 34.2% is within acceptable range for biomarker-selected oncology trials (industry benchmark: 30-40%)
qualityℹ️ info
Italy sites (3) not yet activated due to AIFA regulatory delay — 15 patients forecasted from these sites at risk
complianceMonthly Enrollment vs Target
Apr 2025
Actual: 0
Projected: 0
Target: 0
May 2025
Actual: 0
Projected: 0
Target: 0
Jun 2025
Actual: 0
Projected: 0
Target: 5
Jul 2025
Actual: 0
Projected: 0
Target: 12
Aug 2025
Actual: 0
Projected: 0
Target: 20
Sep 2025
Actual: 3
Projected: 3
Target: 28
Oct 2025
Actual: 14
Projected: 14
Target: 35
Nov 2025
Actual: 32
Projected: 32
Target: 55
Dec 2025
Actual: 48
Projected: 48
Target: 75
Jan 2026
Actual: 71
Projected: 71
Target: 100
Feb 2026
Actual: 94
Projected: 94
Target: 125
Mar 2026
Actual: 112
Projected: 112
Target: 150
Apr 2026
Projected: 132
Target: 175
May 2026
Projected: 155
Target: 200
Jun 2026
Projected: 180
Target: 230
Jul 2026
Projected: 208
Target: 260
Aug 2026
Projected: 238
Target: 290
Sep 2026
Projected: 270
Target: 320
Oct 2026
Projected: 305
Target: 355
Nov 2026
Projected: 342
Target: 390
Dec 2026
Projected: 380
Target: 420
Jan 2027
Projected: 420
Target: 450
Feb 2027
Projected: 462
Target: 480
Mar 2027
Projected: 505
Target: 510
Actual Projected Target
Site Performance
| Site | Country | Enrollment | Screen Fail % | Query Rate | Status |
|---|---|---|---|---|---|
| Institut Gustave Roussy | France | 24/18 | 28% | 1.2 | |
| Charite Berlin | Germany | 19/16 | 31.5% | 1.8 | |
| CHUV Lausanne | Switzerland | 15/14 | 25% | 2 | |
| Hospital Clinic Barcelona | Spain | 8/14 | 42% | 3.5 | |
| HUG Geneve | Switzerland | 12/10 | 30% | 1.5 | |
| UZ Leuven | Belgium | 5/10 | 50% | 4.2 | |
| Erasmus MC Rotterdam | Netherlands | 11/10 | 27% | 1.4 | |
| LMU Klinikum Munich | Germany | 14/12 | 33% | 2.3 |
Study Timeline
First Subject First Visit (FSFV)completed
Planned: 2025-10-01Actual: 2025-10-15
25% Enrollmentcompleted
Planned: 2026-02-15Actual: 2026-02-28
50% Enrollmenton track
Planned: 2026-06-01
Interim Analysis (IA1)on track
Planned: 2026-10-01
100% Enrollmentat risk
Planned: 2027-01-15
Database Lockon track
Planned: 2027-09-01
Primary Analysis CSRon track
Planned: 2027-12-01
Weekly Quality Trend
Open Queries
Protocol Deviations
SAEs Reported